Drug Trial Radar · NCT05621317
A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy
Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
95
Actual
Start
Feb 9, 2023
Primary completion
Sep 26, 2025
Study completion Jun 2028
Sponsor
- Lead sponsor
- Aravax Pty LtdIndustry
- Sponsor type
- Industry
- First posted
- Nov 18, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 4 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The overall aims of this study are to demonstrate that treatment with PVX108 immunotherapy has an acceptable safety profile and is effective for reducing clinical reactivity to peanut protein in children and adolescents with peanut allergy.
Conditions
- Peanut Allergy
- Peanut Hypersensitivity
- Peanut-Induced Anaphylaxis
- Immune System Diseases
Interventions
PVX-108Biological
PVX108 comprises a mixture of peptides that represent sequences from peanut allergens
PlaceboBiological
Matching placebo comprises the formulation vehicle without peptides
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ratio of maximum tolerated dose (MTD) of peanut protein at the Week 46 double blind placebo-controlled food challenge (DBPCFC) relative to baseline in children aged 4 to 11 years treated with PVX108 compared to placeboTime frame: 46 weeks
Locations
14 sites in 2 countries. Site status is shown where the registry gives one.
Arkansas Children's Research Institute
Little Rock, Arkansas
Peninsula Research Associates
Rolling Hills Estates, California
Children's Healthcare of Atlanta
Atlanta, Georgia
Riley Children's Hospital at IU
Indianapolis, Indiana
Johns Hopkins Hospital
Baltimore, Maryland
IAA Clinical Research
Chevy Chase, Maryland
Massachusetts General Hospital
Boston, Massachusetts
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Sydney Children's Hospital
Randwick, New South Wales, Australia
The Children's Hospital at Westmead
Westmead, New South Wales, Australia
Queensland Children's Hospital
South Brisbane, Queensland, Australia
Women's and Children's Hospital
North Adelaide, South Australia, Australia
The Royal Children's Hospital Melbourne
Parkville, Victoria, Australia
Perth Children's Hospital
Nedlands, Western Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.